GlassScriptPhysician profile
Stephen N Abramson
NPI 1508835943
$949.19
in general payments reported to CMS, 2019-2025
16 companies · $21.32 in 2025
The $21.32 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $269 · 2021: $285 · 2022: $158 · 2025: $21.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $250.43 | 2019-2020 | |
| Abbott Laboratories | $109.86 | 2021-2025 | Dragonfly Opstar |
| Medtronic Vascular, INC. | $73.50 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.28 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $68.02 | 2021-2022 | |
| Pfizer INC. | $66.66 | 2019-2022 | |
| Amgen INC. | $59.01 | 2019-2022 | |
| Atricure, INC. | $49.57 | 2020-2021 | |
| Impulse Dynamics (USA) INC. | $45.73 | 2022 | |
| Medtronic, INC. | $39.40 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $36.15 | 2021 | |
| Irhythm Technologies, INC. | $21.50 | 2019 | |
| Livanova USA, INC. | $16.93 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.92 | 2019 | |
| Lundbeck LLC | $14.05 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itamar Medical INC | $13.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Abramson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.